Cargando…
The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K(+)-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure
BACKGROUND: CKD is common in heart failure (HF) and associated with morbidity and mortality, yet life-prolonging medications such as renin-angiotensin-aldosterone inhibitors (RAASi) are underused due to risk of hyperkalaemia. Sodium zirconium cyclosilicate (SZC) is a potassium-binding medication tha...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258742/ https://www.ncbi.nlm.nih.gov/pubmed/34229607 http://dx.doi.org/10.1186/s12882-021-02439-2 |